Literature DB >> 1568219

Transcriptional and posttranscriptional activation of urokinase plasminogen activator gene expression in metastatic tumor cells.

B R Henderson1, W P Tansey, S M Phillips, I A Ramshaw, R F Kefford.   

Abstract

Urokinase plasminogen activator (uPA) is a serine protease which has frequently been implicated in the process of tumor cell invasion and metastasis. The degree of expression and mode(s) of regulation of the uPA gene in metastatic compared with nonmetastatic tumor cells have not yet been addressed. We have cloned and sequenced a full-length rat uPA complementary DNA and utilized Northern blot analysis to report that the uPA gene is expressed at levels 3.5- to 70-fold higher in metastatic cell lines than in nonmetastatic cell lines derived from two independent rat mammary adenocarcinomas. Nuclear run-on assays and RNA half-life estimations indicated that metastatic MAT 13762 rat mammary adenocarcinoma cells expressed 3.5-fold higher levels of uPA RNA than a nonmetastatic derivative (J-clone), due to a combined increase in uPA gene transcription and cytoplasmic RNA stability. By contrast, uPA RNA (and enzyme) levels were elevated by up to 70-fold in metastatic clones of dimethylbenz(a)anthracene-induced rat mammary adenocarcinoma (DMBA-8) due to predominantly posttranscriptional mechanisms. Moreover, treatment of nonmetastatic DMBA-8 cell lines with protein synthesis inhibitors led to an increase in nuclear and cytoplasmic uPA RNA levels, without altering the rate of uPA gene transcription. These results suggest that in addition to gene transcription, posttranscriptional events localized in the nucleus and cytoplasm are key determinants of uPA gene activation in rat mammary adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1568219

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  New nucleotide sequence data on the EMBL File Server.

Authors: 
Journal:  Nucleic Acids Res       Date:  1992-08-25       Impact factor: 16.971

2.  Protein synthesis and urokinase mRNA metabolism.

Authors:  Sreerama Shetty
Journal:  Mol Cell Biochem       Date:  2005-03       Impact factor: 3.396

3.  Cytoplasmic-nuclear shuttling of the urokinase mRNA binding protein regulates message stability.

Authors:  Sreerama Shetty
Journal:  Mol Cell Biochem       Date:  2002-08       Impact factor: 3.396

Review 4.  Invasion and metastasis.

Authors:  D Boyd
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

5.  Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.

Authors:  S N Wagner; M J Atkinson; S Thanner; C Wagner; M Schmitt; O Wilhelm; M Rotter; H Höfler
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

6.  Multiple instability-regulating sites in the 3' untranslated region of the urokinase-type plasminogen activator mRNA.

Authors:  R Nanbu; P A Menoud; Y Nagamine
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

Review 7.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Induction of brain microvascular endothelial cell urokinase expression by Cryptococcus neoformans facilitates blood-brain barrier invasion.

Authors:  Jamal Stie; Deborah Fox
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

9.  Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.

Authors:  E F Solomayer; I J Diel; D Wallwiener; S Bode; G Meyberg; M Sillem; C Gollan; M D Kramer; U Krainick; G Bastert
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Expression of the nm23-2/NDP kinase alpha gene in rat mammary and oral carcinoma cells of varying metastatic potential.

Authors:  B R Henderson
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.